BR112022014646A2 - Terapia anti-bcma em transtornos autoimunes - Google Patents

Terapia anti-bcma em transtornos autoimunes

Info

Publication number
BR112022014646A2
BR112022014646A2 BR112022014646A BR112022014646A BR112022014646A2 BR 112022014646 A2 BR112022014646 A2 BR 112022014646A2 BR 112022014646 A BR112022014646 A BR 112022014646A BR 112022014646 A BR112022014646 A BR 112022014646A BR 112022014646 A2 BR112022014646 A2 BR 112022014646A2
Authority
BR
Brazil
Prior art keywords
autoimmune disorders
bcma therapy
bcma
therapy
anca
Prior art date
Application number
BR112022014646A
Other languages
English (en)
Portuguese (pt)
Inventor
Mensah Kofi
Plenge Robert
Roy Sophie
Zaller Dennis
Dovey Jennifer
Saenz Steven
Henault Jill
Doykan Camille
Calvino Jenna
Jin Xi
Paquette Joseph
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112022014646A2 publication Critical patent/BR112022014646A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022014646A 2020-02-12 2021-02-11 Terapia anti-bcma em transtornos autoimunes BR112022014646A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (1)

Publication Number Publication Date
BR112022014646A2 true BR112022014646A2 (pt) 2022-09-13

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014646A BR112022014646A2 (pt) 2020-02-12 2021-02-11 Terapia anti-bcma em transtornos autoimunes

Country Status (11)

Country Link
US (1) US20240052064A1 (enExample)
EP (1) EP4103224A4 (enExample)
JP (1) JP7783183B2 (enExample)
KR (1) KR20220141306A (enExample)
CN (1) CN115551539A (enExample)
AU (1) AU2021221123A1 (enExample)
BR (1) BR112022014646A2 (enExample)
CA (1) CA3169696A1 (enExample)
IL (1) IL295471A (enExample)
MX (1) MX2022009784A (enExample)
WO (1) WO2021163329A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用
WO2026033437A1 (en) * 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026037514A1 (en) * 2024-08-13 2026-02-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016302881B2 (en) * 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
JP2020524512A (ja) * 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
CA3080904A1 (en) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen

Also Published As

Publication number Publication date
IL295471A (en) 2022-10-01
KR20220141306A (ko) 2022-10-19
MX2022009784A (es) 2022-09-09
US20240052064A1 (en) 2024-02-15
JP2023514224A (ja) 2023-04-05
JP7783183B2 (ja) 2025-12-09
CA3169696A1 (en) 2021-08-19
EP4103224A1 (en) 2022-12-21
CN115551539A (zh) 2022-12-30
AU2021221123A1 (en) 2022-10-06
WO2021163329A1 (en) 2021-08-19
EP4103224A4 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
MX2022009784A (es) Terapia anti-bcma en trastornos autoinmunes.
BR112021006344A2 (pt) vetores de raav para o tratamento de gangliosidose gm1 e gm2
Linderman et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season
PH12015500435A1 (en) Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX395639B (es) Composiciones y métodos para el agotamiento de células cd137+.
MX2017013113A (es) Anticuerpos anti-pacap y sus usos.
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
MX2018002293A (es) Sistemas y métodos para las llamadas variantes de alta precisión.
MX2016014210A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
BR112014008764A8 (pt) Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide
MX386491B (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
Ljoså et al. Mental distress among shift workers in Norwegian offshore petroleum industry—relative influence of individual and psychosocial work factors
BR112015022462A2 (pt) inibidores de ido
Rasmussen et al. Neurodevelopmental disorders associated with dosage imbalance of ZBTB20 correlate with the morbidity spectrum of ZBTB20 candidate target genes
MX2021007719A (es) Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso.
JOP20240019A1 (ar) مركبات لعلاج الآلام، خاصةً ألم الاعتلال العصبي، و/أو أمراض أو اضطرابات أخرى مرتبطة بمستقبل at2r و/أو الإشارات التي يتم إرسالها بواسطة المستقبل at2r
EA202092302A1 (ru) Антитела к trem-1 и их применения
BR112014027991A2 (pt) agentes para neutralização de influenza
NI202000005A (es) Agentes, usos y métodos para el tratamiento
Mo et al. Haploidentical hematopoietic stem cell transplantation for myelodysplastic syndrome
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.